Skip to main content

Table 4 Physical and 2DE structural and functional parameters at 4 weeks (final)

From: The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

  Level Parameter Group
Control Empagliflozin
   Body weight [gr] 398 ± 46 382 ± 21
Apical level Systolic LVESA [mm2] 52.4 ± 5.4*** 53.5 ± 5.1***
LVIDs [mm] 7.9 ± 0.5*** 7.8 ± 0.5***
Diastolic LVEDA [mm2] 69.3 ± 5.6** 77.1 ± 5.3***
LVIDd [mm] 9.5 ± 0.5** 9.0 ± 0.4*
Function FS [%] 17.6 ± 4.2** 13.7 ± 4.0**
FAC [%] 27.6 ± 3.8*** 31.0 ± 3.5***
EF [%] 37.3 ± 6.8** 32.3 ± 6.4**
Papillary muscles level Systolic LVESA [mm2] 60.6 ± 4.4*** 57.5 ± 4.0***
LVIDs [mm] 8.1 ± 0.5*** 8.2 ± 0.5***
Diastolic LVEDA [mm2] 89.2 ± 4.8** 85.3 ± 4.5***
LVIDd [mm] 9.8 ± 0.3*** 9.8 ± 0.3***
Function FS [%] 18.6 ± 3.4*** 17.6 ± 3.2***
FAC [%] 34.1 ± 3.7** 33.5 ± 3.4**
EF [%] 40.1 ± 5.8*** 39.4 ± 5.4**
  1. Abbs. as in Table 2. * P < 0.05 vs. baseline, ** P < 0.01 vs. baseline and *** P < 0.001 vs. baseline
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840